Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

Abstract This study evaluated the safety and immunogenicity of BNT162b2 vaccine in patients with hematological malignancies. Antibodies blocking spike binding to immobilized ACE-2 (NAb) correlated with anti-Spike (S) IgG d42 titers (Spearman r = 0.865, p < 0.0001), and an anti-S IgG d42 level ≥31...

Full description

Bibliographic Details
Main Authors: Florent Malard, Béatrice Gaugler, Joel Gozlan, Lucie Bouquet, Djeneba Fofana, Lama Siblany, Deborah Eshagh, Olivier Adotevi, Caroline Laheurte, Laure Ricard, Rémy Dulery, Nicolas Stocker, Zoe van de Wyngaert, Alexis Genthon, Anne Banet, Mara Memoli, Souhila Ikhlef, Simona Sestilli, Anne Vekhof, Eolia Brissot, Zora Marjanovic, Yannick Chantran, Nancy Cuervo, Eric Ballot, Laurence Morand-Joubert, Mohamad Mohty
Format: Article
Language:English
Published: Nature Publishing Group 2021-08-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-021-00534-z

Internet

https://doi.org/10.1038/s41408-021-00534-z

Similar Items